Checkmate Pharmaceuticals, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2021. For the quarter, Loss from operations was $18,955,000 against $8,271,000 a year ago. Net loss was $18,970,000 against $8,348,000 a year ago. Net loss per share attributable to common stockholders – basic and diluted was $0.88 against $7.37 a year ago. For the six months, Loss from operations was $33,136,000 against $16,094,000 a year ago. Net loss was $33,098,000 against $16,149,000 a year ago. Net loss per share attributable to common stockholders – basic and diluted was $1.53 against $13.81 a year ago.